深圳市海王英特龍生物技術股份有限公司

SHENZHEN NEPTUNUS INTERLONG BIO-TECHNIQUE COMPANY LIMITED*

(a joint stock limited company incorporated in the People's Republic of China)

(Stock code: 8329)

ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2026

CHARACTERISTICS OF GEM OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE "STOCK EXCHANGE")

GEM has been positioned as a market designed to accommodate small and mid-sized companies to which a higher investment risk may be attached than other companies listed on the Stock Exchange. Prospective investors should be aware of the potential risks of investing in such companies and should make the decision to invest only after due and careful consideration.

Given that the companies listed on GEM are generally small and midsized companies, there is a risk that securities traded on GEM may be more susceptible to high market volatility than securities traded on the Main Board of the Stock Exchange and no assurance is given that there will be a liquid market in the securities traded on GEM.

This announcement, for which the directors (the "Directors") of Shenzhen Neptunus Interlong Bio-technique Company Limited (the "Company") collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of the Stock Exchange (the "GEM Listing Rules") for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

* *For identification purpose only*

INTERIM RESULTS (UNAUDITED)

The board of directors (the "Board") of the Company is pleased to present the unaudited condensed consolidated interim financial statements of the Company and its subsidiaries (collectively the "Group") for the six months ended 30 June 2026 (the "Reporting Period"), together with the unaudited comparative figures for the corresponding period of 2025.

CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME (UNAUDITED)

For the six months ended 30 June 2026

		For the six months ended 30 June	
		2026	2025
		RMB'000	RMB'000
	Notes	**(Unaudited)**	(Unaudited)
Revenue	4	**436,165**	495,920
Cost of sales		**(302,816)**	(337,566)
Gross profit		**133,349**	158,354
Other revenue and other net income	4	**1,539**	9,191
Selling and distribution expenses		**(58,645)**	(74,120)
Administrative expenses		**(45,440)**	(45,050)
Other operating expenses		**(15,601)**	(22,241)
Net impairment of trade and other receivables		**(3,557)**	(1,142)
Profit from operations		**11,645**	24,992
Finance costs	6(a)	**(1,754)**	(2,246)
Profit before taxation	6	**9,891**	22,746
Income tax expense	7	**(981)**	(705)
Profit and total comprehensive income for the period		**8,910**	22,041
Profit and total comprehensive income for the period attributable to:			
Owners of the Company		**7,042**	19,065
Non-controlling interests		**1,868**	2,976
		8,910	22,041
Earnings per share			
Basic and diluted	9	**RMB0.42 cents**	RMB1.14 cents

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION (UNAUDITED)

As at 30 June 2026

	Notes	**At 30 June 2026 RMB'000 (Unaudited)**	At 31 December 2025 RMB'000 (Audited)
ASSETS AND LIABILITIES			
Non-current assets			
Property, plant and equipment	10	**177,575**	185,113
Right-of-use assets	10	**75,797**	76,304
Intangible assets		**117,440**	119,452
Deposits for acquisition of property, plant and equipment		**202**	277
Deposit for acquisition of land use right		**9,817**	9,817
Deferred tax assets		**2,922**	3,126
Time deposits		**20,500**	10,000
		404,253	404,089
Current assets			
Tax recoverable		**690**	780
Inventories		**165,149**	158,970
Trade and other receivables	11	**287,290**	283,365
Time deposits		**–**	10,000
Bank balances and cash		**212,257**	199,357
		665,386	652,472
Current liabilities			
Trade and other payables	12	**226,118**	236,385
Contract liabilities		**10,214**	13,314
Interest-bearing borrowings	13	**92,529**	68,276
Lease liabilities	14	**1,832**	1,985
Current taxation		**2,287**	4,697
		332,980	324,657
Net current assets		**332,406**	327,815
Total assets less current liabilities		**736,659**	731,904

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION (UNAUDITED) (CONTINUED)

As at 30 June 2026

	Notes	**At 30 June 2026 RMB'000 (Unaudited)**	At 31 December 2025 RMB'000 (Audited)
Non-current liabilities			
Interest-bearing borrowings	13	**1,277**	2,727
Deferred revenue		**589**	589
Lease liabilities	14	**750**	–
Deferred tax liabilities		**24,254**	24,574
		26,870	27,890
Net assets		**709,789**	704,014
EQUITY			
Equity attributable to owners of the Company			
Share capital	15	**167,800**	167,800
Reserves		**486,698**	479,656
Total		**654,498**	647,456
Non-controlling interests		**55,291**	56,558
Total equity		**709,789**	704,014

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (UNAUDITED)

For the six months ended 30 June 2026

	Attributable to owners of the Company							
	Share capital RMB'000	**Share premium RMB'000**	**Capital reserve RMB'000**	**Statutory reserve fund RMB'000**	**Retained earnings RMB'000**	**Sub-total RMB'000**	**Non-controlling interests RMB'000**	**Total RMB'000**
At 1 January 2025 (audited)	167,800	554,844	(188,494)	53,718	345,315	933,183	92,916	1,026,099
Profit and total comprehensive income for the period	–	–	–	–	19,065	19,065	2,976	22,041
Dividend paid to owners of the Company (Note 8)	–	–	–	–	(244,988)	(244,988)	–	(244,988)
Dividend paid to non-controlling interests	–	–	–	–	–	–	(23,999)	(23,999)
Transfer to statutory reserve fund	–	–	–	76	(76)	–	–	–
At 30 June 2025 (unaudited)	167,800	554,844	(188,494)	53,794	119,316	707,260	71,893	779,153
At 1 January 2026 (audited)	**167,800**	**554,844**	**(188,494)**	**55,451**	**57,855**	**647,456**	**56,558**	**704,014**
Profit and total comprehensive income for the period	**–**	**–**	**–**	**–**	**7,042**	**7,042**	**1,868**	**8,910**
Dividend paid to non-controlling interests	**–**	**–**	**–**	**–**	**–**	**–**	**(3,135)**	**(3,135)**
At 30 June 2026 (unaudited)	**167,800**	**554,844**	**(188,494)**	**55,451**	**64,897**	**654,498**	**55,291**	**709,789**

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (UNAUDITED)

For the six months ended 30 June 2026

	For the six months ended 30 June	
	2026	2025
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
Operating cash flows before working capital changes		
Changes in working capital	**31,304**	42,106
(Increase)/Decrease in inventories	**(7,029)**	22,402
(Increase)/Decrease in trade and other receivables	**(7,482)**	13,774
Decrease in trade and other payables and contract liabilities	**(13,367)**	(35,962)
Cash generated from operations	**3,426**	42,320
Income tax paid	**(3,417)**	(1,149)
Net cash generated from operating activities	**9**	41,171
Investing activities		
Deposits paid for acquisition of property, plant and equipment	**(277)**	(1,263)
Additions to intangible assets	**–**	(1,295)
Purchase of property, plant and equipment	**(3,079)**	(5,371)
Proceeds from disposal of property, plant and equipment	**–**	1,024
Interest received	**389**	1,553
Placement of time deposit	**(10,500)**	–
Redemption of time deposit	**10,000**	95,000
Net cash (used in)/generated from investing activities	**(3,467)**	89,648

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (UNAUDITED) (CONTINUED)

For the six months ended 30 June 2026

	For the six months ended 30 June	
	2026	2025
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
Financing activities		
Repayment of interest-bearing bank borrowings	**(9,076)**	(15,118)
Proceeds from interest-bearing bank borrowings	**31,879**	12,781
Interest paid	**(1,695)**	(2,174)
Payment of lease liabilities	**(1,615)**	(1,418)
Dividend paid to owners of the Company	**–**	(244,988)
Dividend paid to non-controlling interest	**(3,135)**	(23,999)
Net cash generated from/(used in) financing activities	**16,358**	(274,916)
Net increase/(decrease) in cash and cash equivalents	**12,900**	(144,097)
Cash and cash equivalents at the beginning of the period	**199,357**	283,424
Cash and cash equivalents at the end of the period	**212,257**	139,327
Analysis of cash and cash equivalents at 30 June		
Bank balances and cash	**212,257**	139,327

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the six months ended 30 June 2026

1. CORPORATE INFORMATION

Shenzhen Neptunus Interlong Bio-technique Company Limited (the "Company") is a limited liability company incorporated and domiciled in the People's Republic of China (the "PRC"). The address of its registered office is Suite 1702, Neptunus Yinhe Technology Mansion, 1 Keji Middle 3rd Road, Maling Community, Yuehai Sub-district, Nanshan District, Shenzhen, the PRC and its principal place of business is the PRC. The Company's shares are listed on GEM of The Stock Exchange of Hong Kong Limited.

The Group is controlled by Shenzhen Neptunus Bio-engineering Company Limited ("Neptunus Bio-engineering"), a limited liability company incorporated and domiciled in the PRC and its shares are listed on the Shenzhen Stock Exchange. The ultimate parent company of the Group is Shenzhen Neptunus Holding Group Limited ("Neptunus Holding"), a company incorporated in the PRC.

The principal activities of the Group include the development, production and sales of medicines and medical devices, the research and development of modern biological technology business and the purchase and sales of medicines, healthcare food products and medical devices. The Group's operations are based in the PRC.

2. BASIS OF PREPARATION AND ACCOUNTING POLICIES

The condensed consolidated interim financial statements for the six months ended 30 June 2026 have been prepared in accordance with the applicable disclosure provision of the GEM Listing Rules on the Stock Exchange, including compliance with Hong Kong Accounting Standard ("HKAS") 34, "Interim Financial Reporting" as issued by the Hong Kong Institute of Certified Public Accountants ("HKICPA"). It is authorised for issue on 25 August 2026.

The preparation of the condensed consolidated interim financial statements in conformity with HKAS 34 requires the management to make judgements, estimates and assumptions that affect the application of policies and the reported amounts of assets and liabilities, income and expenses on a year to date basis. Actual results may differ from these estimates.

The condensed consolidated interim financial statements have been prepared in accordance with the same accounting policies adopted in the annual financial statements for the year ended 31 December 2025, except for the adoption of the amended HKFRS Accounting Standards as issued by the HKICPA which are relevant to and effective for the Group's financial statements for the annual period beginning on 1 January 2026 as disclosed in note 3(a) to this condensed consolidated interim financial statements. The condensed consolidated interim financial statements do not include all the information and disclosures required for annual financial statements, and should be read in conjunction with the financial statements of the Group for the year ended 31 December 2025.

The measurement basis used in the preparation of these financial statements is the historical cost basis. These financial statements are presented in Renminbi ("RMB"), which is also the functional currency of the Company and all amounts are rounded to the nearest thousand except where otherwise indicated.

The condensed consolidated interim financial statements are unaudited.

3. NEW AND AMENDED HKFRS ACCOUNTING STANDARDS

(a) Amended HKFRS Accounting Standards effective on 1 January 2026

During the Reporting Period, the Group has applied for the first time the following amended HKFRS Accounting Standards as issued by the HKICPA, which are relevant to the Group's operations and effective for the Group's consolidated financial statements for the annual period beginning on 1 January 2026:

Amendments to HKFRS 9 and HKFRS 7	Amendments to the Classification and Measurement of Financial Instruments
Amendments to HKFRS 9 and HKFRS 7	Contracts Referencing Nature-dependent Electricity
Amendments to HKFRS Accounting Standards	Annual Improvements to HKFRS Accounting Standards – Volume 11

The adoption of the amended HKFRS Accounting Standards had no material impact on how the results and financial position for the current and prior periods have been prepared and presented.

(b) Issued but not yet effective HKFRS Accounting Standards

At the date of authorisation of the Group's condensed consolidated interim financial statements, certain new and amended HKFRS Accounting Standards have been published but are not yet effective, and have not been adopted early by the Group.

HKFRS 18	Presentation and Disclosure in Financial Statements[2]
HKFRS 19	Subsidiaries without Public Accountability: Disclosures[2]
Amendments to HKAS 21	Translation to a Hyperinflationary Presentation Currency[2]
Amendments to HKFRS 10 and HKAS 28	Sale or Contribution of Assets between an Investor and its Associate or Joint Venture[1]
Amendments to Hong Kong Interpretation 5	Hong Kong Interpretation 5 Presentation of Financial Statements – Classification by the Borrower of a Term Loan that Contains a Repayment on Demand Clause[2]

1 No mandatory effective date yet determined but available for adoption

2 Effective for annual periods beginning on or after 1 January 2027

The directors are currently assessing the possible impact of these new and amended HKFRS Accounting Standards on the Group's results and financial position in the first year of application. The directors consider that these amendments are unlikely to have a material impact on the Group's condensed consolidated financial statements.

4. REVENUE, OTHER REVENUE AND OTHER NET INCOME

Revenue arises mainly from manufacturing and selling of medicines, healthcare products and medical devices.

	For the six months ended 30 June	
	2026	2025
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
Manufacturing and selling of medicines and medical devices	**216,828**	251,003
Sales and distribution of medicines, healthcare products and medical devices	**219,337**	244,917
	436,165	495,920

	For the six months ended 30 June	
	2026	2025
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
Other revenue and other net income		
Interest income from bank deposits	**389**	1,553
Reversal of write down of inventories	**69**	201
Government subsidies		
– directly recognised in profit or loss	**958**	1,679
Write-back of trade and other payables	**–**	5,642
Others	**123**	116
	1,539	9,191

5. SEGMENT REPORTING

The Group manages its business by divisions, which are organised by a mixture of both business lines (products and services) and geographical location. In a manner consistent with the way in which information is reported internally to the Group's executive directors, being the chief operating decision maker, for the purpose of resources allocation and performance assessment, the Group has presented the following two reportable segments.

(i) Manufacturing and selling of medicines and medical devices; and

(ii) Sales and distribution of medicines, healthcare products and medical devices.

Currently, all of the Group's activities above are carried out in the PRC. No reportable operating segment has been aggregated.

(a) Segment results, assets and liabilities

Segment assets include all current and non-current assets with the exception of deferred tax assets. Segment liabilities include all current and non-current liabilities with the exception of current taxation and deferred tax liabilities.

Revenue and expenses are allocated to the reportable segments with reference to revenue generated by and expenses incurred by those segments except for corporate income and expenses which are not directly attributable to the business activities of any reportable segment. Inter-segment revenue is priced with reference to prices charged to external parties for similar orders.

5. **SEGMENT REPORTING (CONTINUED)**

(a) Segment results, assets and liabilities (Continued)

For the six months ended 30 June	Manufacturing and selling of medicines and medical devices		Sales and distribution of medicines, healthcare products and medical devices		Total	
	2026	2025	**2026**	2025	**2026**	2025
	RMB'000	RMB'000	**RMB'000**	RMB'000	**RMB'000**	RMB'000
	(Unaudited)	(Unaudited)	**(Unaudited)**	(Unaudited)	**(Unaudited)**	(Unaudited)
Segment revenue						
Revenue from external customers	**216,828**	251,003	**219,337**	244,917	**436,165**	495,920
Inter-segment revenue	**17,908**	24,579	**–**	–	**17,908**	24,579
Reportable segment revenue	**234,736**	275,582	**219,337**	244,917	**454,073**	520,499
Reportable segment profit/(loss)	**(100,547)**	(3,562)	**112,229**	27,644	**11,682**	24,082
Net reversal/(impairment) of:						
– trade receivables	**156**	(112)	**(734)**	1,416	**(578)**	1,304
– other receivables	**(637)**	(1,467)	**(2,342)**	(979)	**(2,979)**	(2,446)
Write down of inventories	**(786)**	(1,590)	**(133)**	(895)	**(919)**	(2,485)
Reversal of write-down of inventories	**62**	201	**7**	–	**69**	201

	At 30 June 2026	At 31 December 2025	**At 30 June 2026**	At 31 December 2025	**At 30 June 2026**	At 31 December 2025
	RMB'000	RMB'000	**RMB'000**	RMB'000	**RMB'000**	RMB'000
	(Unaudited)	(Audited)	**(Unaudited)**	(Audited)	**(Unaudited)**	(Audited)
Reportable segment assets	**688,144**	715,542	**727,795**	650,527	**1,415,939**	1,366,069
Additions to non-current segment assets (other than deferred tax assets) during the period/year	**3,412**	16,183	**2,172**	1,397	**5,584**	17,580
Reportable segment liabilities	**229,706**	352,353	**453,515**	284,337	**683,221**	636,690

The Group's customer base is diversified and no customer with whom transactions have exceeded 10% of the Group's revenue for the six months ended 30 June 2026 and 2025.

5. SEGMENT REPORTING (CONTINUED)

(b) Reconciliations of reportable segment revenue, profit before taxation, assets and liabilities

	For the six months ended 30 June	
	2026	2025
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
Revenue		
Reportable segment revenue	**454,073**	520,499
Elimination of inter-segment revenue	**(17,908)**	(24,579)
Consolidated revenue	**436,165**	495,920
Profit before taxation		
Reportable segment profit	**11,682**	24,082
Elimination of inter-segment profit	**(1,039)**	(499)
Reportable segment profit derived from the Group's external customers	**10,643**	23,583
Unallocated corporate expenses	**(752)**	(837)
Consolidated profit before taxation	**9,891**	22,746

5. SEGMENT REPORTING (CONTINUED)

(b) Reconciliations of reportable segment revenue, profit before taxation, assets and liabilities (Continued)

	At 30 June 2026 RMB'000 (Unaudited)	At 31 December 2025 RMB'000 (Audited)
Assets		
Reportable segment assets	**1,415,939**	1,366,069
Elimination of inter-segment receivables	**(349,912)**	(313,414)
	1,066,027	1,052,655
Tax recoverable	**690**	780
Deferred tax assets	**2,922**	3,126
Consolidated total assets	**1,069,639**	1,056,561
Liabilities		
Reportable segment liabilities	**683,221**	636,690
Elimination of inter-segment payables	**(349,912)**	(313,414)
	333,309	323,276
Current taxation	**2,287**	4,697
Deferred tax liabilities	**24,254**	24,574
Consolidated total liabilities	**359,850**	352,547

5. **SEGMENT REPORTING (CONTINUED)**

(c) Revenue from major products and services

The following is an analysis of the Group's revenue from its major products and services:

	For the six months ended 30 June	
	2026	2025
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
Sales of medicines and healthcare products	**363,485**	400,411
Sales of medical devices	**72,680**	95,509
	436,165	495,920

(d) Geographical information

The Group's revenue was derived from business activities in the PRC and the specified non-current assets of the Group were located in the PRC. Accordingly, no analysis by geographical segment is provided.

(e) Disaggregation of revenue from contracts with customers

The Group derives revenue from sales of medicines, healthcare products and medical devices at a point in time from the following types of customers:

	Hospital RMB'000 (Unaudited)	**Pharmacy RMB'000 (Unaudited)**	**Others RMB'000 (Unaudited)**	**Total RMB'000 (Unaudited)**
For the six months ended 30 June 2026				
Manufacturing and selling of medicines and medical devices	**27,761**	**188,063**	**1,004**	**216,828**
Sales and distribution of medicines, healthcare products and medical devices	**10,274**	**209,063**	**–**	**219,337**
	38,035	**397,126**	**1,004**	**436,165**

	Hospital RMB'000 (Unaudited)	Pharmacy RMB'000 (Unaudited)	Others RMB'000 (Unaudited)	Total RMB'000 (Unaudited)
For the six months ended 30 June 2025				
Manufacturing and selling of medicines and medical devices	26,917	223,135	951	251,003
Sales and distribution of medicines, healthcare products and medical devices	7,408	237,509	–	244,917
	34,325	460,644	951	495,920

6. PROFIT BEFORE TAXATION

Profit before taxation is arrived at after charging/(crediting):

		For the six months ended 30 June	
		2026	2025
		RMB'000	RMB'000
		(Unaudited)	(Unaudited)
(a)	**Finance costs**		
	Interest on bank loans and other borrowings	**1,695**	2,174
	Finance charges on lease liabilities	**59**	72
		1,754	2,246
(b)	**Staff costs (including directors' emoluments)**		
	Salaries, wages and other benefits	**68,177**	71,417
	Contributions to defined contribution retirement plans	**10,304**	12,531
		78,481	83,948
(c)	**Other items**		
	Depreciation of right-of-use assets	**2,660**	2,314
	Amortisation of intangible assets*	**2,012**	1,862
	Depreciation of property, plant and equipment	**10,956**	10,881
	Cost of inventories	**292,650**	333,206
	Research and development costs*	**14,151**	16,848
	Net impairment/(reversal) of:		
	– trade receivables	**578**	(1,304)
	– other receivables	**2,979**	2,446
	Loss on disposal of property, plant and equipment, net*	**13**	106
	Write down of inventories*	**919**	2,485
	Reversal of write-down of inventories	**(69)**	(201)
	Auditor's remuneration		
	– audit services	**–**	–
	– non-audit services	**242**	330
	Lease charges in respect of short term leases	**313**	804

* These amounts have been included in "Other operating expenses" in the condensed consolidated statement of profit or loss and other comprehensive income.

7. INCOME TAX EXPENSE

	For the six months ended 30 June	
	2026	2025
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
Current tax		
PRC Enterprise Income Tax ("EIT") Current	**1,095**	2,367
Under-provision/(Over-provision) in respect of prior year	**2**	(995)
Deferred tax		
Current year	**(116)**	(667)
	981	705

Hong Kong Profits Tax has not been provided as the Group had no assessable profits subject to Hong Kong Profits Tax during the Reporting Period (30 June 2025: Nil).

During the Reporting Period, three (30 June 2025: three) subsidiaries of the Group established in the PRC are qualified as "High and New Technology Enterprise". In accordance with the applicable Enterprise Income Tax Law of the PRC, these subsidiaries are subject to the PRC EIT at a preferential rate of 15%.

According to a policy promulgated by the State Tax Bureau of the PRC, enterprises engage in research and development activities are entitled to claim 200% of the research and development expenses incurred in a year as tax deductible expenses in determining the taxable profits for that year ("Super Deduction"). Three (30 June 2025: three) subsidiaries of the Group are eligible to such Super Deduction in ascertaining its assessable profits for the Reporting Period.

The Company and other PRC subsidiaries are subject to the PRC EIT at a rate of 25% for the Reporting Period (30 June 2025: 25%).

8. DIVIDENDS

	For the six months ended 30 June	
	2026	2025
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
Dividend approved and paid during the Reporting Period:		
2024 final dividend of RMB0.005 per ordinary share	**–**	8,390
2024 special dividend of RMB0.141 per ordinary share	**–**	236,598
	–	244,988

The directors do not propose payment of any dividend for the Reporting Period (2025: Nil).

9. EARNINGS PER SHARE

Basic earnings per share

For the six months ended 30 June 2026, the calculation of basic earnings per share has been based on the profit attributable to owners of the Company of approximately RMB7,042,000 (six months ended 30 June 2025: profit of approximately RMB19,065,000) and the weighted average number of 1,678,000,000 ordinary shares in issue for the six months ended 30 June 2026 (six months ended 30 June 2025: 1,678,000,000 ordinary shares).

Diluted earnings per share

Diluted earnings per share for the six-month periods ended 30 June 2026 and 2025 equals to basic earnings per share as there were no potential dilutive ordinary shares outstanding during these periods.

10. PROPERTY, PLANT AND EQUIPMENT AND RIGHT-OF-USE ASSETS

During the Reporting Period, the Group purchased property, plant and equipment at cost of approximately RMB3,431,000 (30 June 2025: RMB5,371,000) and disposed of/wrote off property, plant and equipment at carrying amount of RMB13,000 (30 June 2025: RMB1,079,000), respectively.

In addition, during the Reporting Period, the Group has entered into lease agreements for PRC office and had recognised right-of-use assets amounted to approximately RMB2,153,000 (six months ended 30 June 2025: RMB141,000).

11. TRADE AND OTHER RECEIVABLES

	Notes	**At 30 June 2026 RMB'000 (Unaudited)**	At 31 December 2025 RMB'000 (Audited)
Trade receivables		**167,230**	175,591
Less: expected credit loss ("ECL") allowance		**(31,571)**	(31,053)
		135,659	144,538
Bills receivables	(i)	**17,782**	39,077
		153,441	183,615
Amounts due from fellow subsidiaries		**52,223**	17,210
Amounts due from related companies		**43,382**	41,216
Amount due from an immediate parent company		**8**	–
Amount due from an intermediate parent company		**117**	139
Other receivables		**20,164**	21,308
Value-added tax recoverable		**261**	186
Prepayment and deposits	(ii)	**24,922**	23,940
Less: ECL allowance		**(7,228)**	(4,249)
		133,849	99,750
		287,290	283,365

11. TRADE AND OTHER RECEIVABLES (CONTINUED)

Notes:

(i) These bank acceptance bills matured within one year from date of issue. The Group considered the issuing banks of the bills are of good credit quality and therefore, the ECL allowance of these receivables are considered to be insignificant.

(ii) Prepayment and deposits mainly represent deposits prepaid in advance to suppliers of approximately RMB23,133,000 (31 December 2025: approximately RMB23,400,000), which aged within one year.

(a) Ageing analysis

Based on the invoice dates (which approximate the respective revenue recognition dates), the ageing analysis of the trade and bills receivables net of ECL allowance, was as follows:

Trade receivables

	At 30 June 2026 RMB'000 (Unaudited)	At 31 December 2025 RMB'000 (Audited)
Within 3 months	**121,762**	103,611
4 to 6 months	**6,803**	28,174
7 to 12 months	**5,794**	11,774
Over 1 year	**1,300**	979
	135,659	144,538

Bills receivables

	At 30 June 2026 RMB'000 (Unaudited)	At 31 December 2025 RMB'000 (Audited)
Within 3 months	**14,230**	19,772
4 to 6 months	**3,552**	19,305
	17,782	39,077

11. TRADE AND OTHER RECEIVABLES (CONTINUED)

(b) Impairment of trade receivables

The movement in the ECL allowance of trade receivables is as follows:

	At 30 June 2026 RMB'000 (Unaudited)	At 31 December 2025 RMB'000 (Audited)
Balance at 1 January	**31,053**	24,838
ECL recognised during the period/year	**853**	11,257
ECL reversed during the period/year	**(275)**	–
Amount written off during the period/year	**(60)**	(5,042)
At 30 June/31 December	**31,571**	31,053

(c) Impairment of other receivables

The movement in the ECL allowance of other receivables is as follows:

	At 30 June 2026 RMB'000 (Unaudited)	At 31 December 2025 RMB'000 (Audited)
Balance at 1 January	**4,249**	2,158
ECL recognised during the period/year	**2,979**	2,631
Amount written off during the period/year	**–**	(540)
At 30 June/31 December	**7,228**	4,249

12. TRADE AND OTHER PAYABLES

Included in trade and other payables are trade and bills payables, the ageing analysis of which, based on the invoice date, is as follows:

	At 30 June 2026 RMB'000 (Unaudited)	At 31 December 2025 RMB'000 (Audited)
Within 3 months	**71,332**	81,006
4 to 6 months	**23,742**	12,555
7 to 12 months	**16,629**	5,759
Over 1 year	**16,573**	42,995
Trade payables	**128,276**	142,315
Other payables and accruals	**44,601**	63,107
Amounts due to fellow subsidiaries	**53,067**	30,159
Amount due to an immediate parent company	**119**	800
Amount due to related companies	**55**	4
	226,118	236,385

13. INTEREST-BEARING BORROWINGS

	Note	**At 30 June 2026 RMB'000 (Unaudited)**	At 31 December 2025 RMB'000 (Audited)
Non-current liabilities			
Other borrowings	(a)	**1,277**	2,727
Current liabilities			
Short-term bank loans	(b)	**88,879**	64,064
Other borrowings	(a)	**3,650**	4,212
		92,529	68,276
		93,806	71,003

13. INTEREST-BEARING BORROWINGS (CONTINUED)

Notes:

(a) As at 30 June 2026, other borrowings of RMB4,927,000 (31 December 2025: RMB6,939,000) from a third party were secured by a pledge of the Group's furniture, fixtures and equipment with carrying amount RMB2,201,000 (31 December 2025: RMB2,512,000). The effective interest rate was 6.5% per annum and repayable as follows:

	At 30 June 2026 RMB'000 (Unaudited)	At 31 December 2025 RMB'000 (Audited)
Carrying amount repayable		
Within one year	**3,650**	4,212
In the second year	**1,277**	2,071
In the third to fifth year	**–**	656
	4,927	6,939

(b) As at 30 June 2026, the interest-bearing bank borrowings were denominated in RMB, repayable within one year (31 December 2025: one year), further details were as follows:

– Bank borrowings of RMB61,052,000 (31 December 2025: RMB34,038,000) were secured by a pledge of the Group's buildings with carrying amount RMB20,385,000 (31 December 2025: RMB13,517,000) and guarantee from the non-controlling shareholder of a subsidiary of the Group and subsidiaries of the Group. The effective interest rate was 2.90% to 3.65% per annum (31 December 2025: 2.90% to 3.65%).

– Bank borrowings of RMB27,827,000 (31 December 2025: RMB30,026,000) were guaranteed by a guarantee from a non-controlling shareholder of a subsidiary and a subsidiary of the Group. The effective interest rate was 2.55% to 4.80% per annum (31 December 2025: 2.55% to 4.80%).

14. LEASE LIABILITIES

	At 30 June 2026 RMB'000 (Unaudited)	At 31 December 2025 RMB'000 (Audited)
Total minimum lease payments:		
Due within one year	**1,882**	2,025
Due in the second to fifth years	**759**	–
	2,641	2,025
Future finance charges on leases liabilities	**(59)**	(40)
Present value of leases liabilities	**2,582**	1,985
Present value of minimum lease payments:		
Due within one year	**1,832**	1,985
Due in the second to fifth years	**750**	–
	2,582	1,985
Less: Portion due within one year included under current liabilities	**(1,832)**	(1,985)
Portion due after one year included under non-current liabilities	**750**	–

During the six months ended 30 June 2026, the total cash outflows for the leases are approximately RMB1,928,000 (six months ended 30 June 2025: RMB2,222,000).

15. SHARE CAPITAL

	Number of shares '000	RMB'000
Registered, issued and fully paid:		
At 1 January and 30 June 2026		
– Domestic shares of RMB0.10 each	**1,252,000**	**125,200**
– H shares of RMB0.10 each	**426,000**	**42,600**
	1,678,000	**167,800**

16. COMMITMENTS

(a) Capital commitments:

	At 30 June 2026 RMB'000 (Unaudited)	At 31 December 2025 RMB'000 (Audited)
Property, plant and equipment		
Contracted but not provided for:		
Property, plant and equipment	**984**	648
Land use right	**3,200**	3,200
	4,184	3,848

(b) Lease commitments

At 30 June 2026, the lease commitments for short-term leases are as follows:

	At 30 June 2026 RMB'000 (Unaudited)	At 31 December 2025 RMB'000 (Audited)
Within 1 year	**832**	1,428

17. MATERIAL RELATED PARTY TRANSACTIONS

(a) Related party transactions:

Name of related parties	Relationship	Nature of transaction	Notes	For the six months ended 30 June 2026 RMB'000 (Unaudited)	2025 RMB'000 (Unaudited)
Neptunus Group	Intermediate parent company	Rental of office	(i)(iii)	**807**	716
Shenzhen Shenye Pharmaceutical Development Company Limited	Non-related company (six months ended 30 June 2025: Fellow subsidiary)	Sales of goods	(ii)(iii)	**131**	191
Henan Neptunus Pharmaceutical Group Limited	Fellow subsidiary	Sales of goods	(ii)(iii)	**439**	385
Shandong Neptunus Yinhe Pharmaceutical Company Limited	Fellow subsidiary	Sales of goods	(ii)(iii)	**2,562**	4,479
Shenzhen Neptunus Pharmaceutical Company Limited	Fellow subsidiary	Purchase of finished goods	(ii)(iii)	**23,558**	25,793
		Rental expense	(ii)(iii)	**–**	193
		Sales of goods	(ii)(iii)	**8,601**	13,215
Guangxi Guilin Neptunus Pharmaceutical Company Limited	Fellow subsidiary	Sales of goods	(ii)(iii)	**–**	401
Sulu Neptunus Pharmaceutical Group Company Limited	Fellow subsidiary	Sales of goods	(ii)(iii)	**151**	137
Zhoukou Renhe Pharmaceutical Company Limited	Fellow subsidiary	Sales of goods	(ii)(iii)	**15**	191
Henan Neptunus Yinhe Pharmaceutical Company Limited	Fellow subsidiary	Sales of goods	(ii)(iii)	**–**	431
Anhui Neptunus Pharmaceutical Group Company Limited	Fellow subsidiary	Sales of goods	(ii)(iii)	**53**	164
Nanning Neptunus Jiankang Bio-technology Company Limited	Related company	Purchases of goods	(ii)	**290**	296
Jiangsu Nepstar Pharmaceutical Company Limited	Related company	Sales of goods	(ii)(iv)	**4,662**	6,598
Shenzhen Neptunus Yidianyao Pharmaceutical Company Limited	Related company	Sales of goods	(ii)(iv)	**5,972**	12,300
		Purchase of goods		**–**	185

17. MATERIAL RELATED PARTY TRANSACTIONS (CONTINUED)

(a) Related party transactions: (Continued)

Name of related parties	Relationship	Nature of transaction	Notes	For the six months ended 30 June 2026 RMB'000 (Unaudited)	2025 RMB'000 (Unaudited)
Kashi Neptunus Yinhe Pharmaceutical Company Limited	Fellow subsidiary	Sales of goods	(ii)(iii)	**141**	207
Guangdong Neptunus Medical Group Company Limited	Fellow subsidiary	Sales of goods	(ii)(iii)	**2,834**	2,058
Heilongjiang Province Neptunus Pharmaceutical Company Limited	Fellow subsidiary	Sales of goods	(ii)(iii)	**111**	277
Qingdao Huaren Medical Delivery Company Limited	Fellow subsidiary	Sales of goods	(ii)(iii)	**23**	380
Liaoning Province Nepstar Medical Trading Company Limited	Related company	Sales of goods	(ii)(iv)	**1,874**	3,069
Henan Zuojinming Pharmaceutical Company Limited	Fellow subsidiary	Sales of goods	(ii)(iii)	**372**	576
Henan Neptunus Wenfeng Pharmaceutical Company Limited	Fellow subsidiary	Sales of goods	(ii)(iii)	**–**	101
Shanghai Fangcheng Medical Devices Company Limited	Fellow subsidiary	Sales of goods	(ii)(iii)	**338**	283
Shenzhen Nepstar Health Drugstore Chain Company Limited	Related company	Sales of goods	(ii)(iv)	**1,033**	–

Notes:

(i) Neptunus Group leased office premises to the Group, the rental of office premises was charged at pre-agreed rate with reference to market rates.

(ii) The purchases, sales and rental of storage were transacted in the normal course of business on the same terms as those charged to and contracted with other third party suppliers and customers.

(iii) The ultimate parent company of these related parties is also the ultimate parent company of the Group.

(iv) The director of the immediate parent company, Mr. Zhang Si Min is also the director of the ultimate parent company of the related company.

17. MATERIAL RELATED PARTY TRANSACTIONS (CONTINUED)

(b) Outstanding balances with related parties

Name of related parties	Amounts due from related parties		Amounts due to related parties	
	At 30 June 2026 RMB'000 (Unaudited)	At 31 December 2025 RMB'000 (Audited)	**At 30 June 2026 RMB'000 (Unaudited)**	At 31 December 2025 RMB'000 (Audited)
Amount due from/to an immediate parent company	**8**	–	**119**	800
Amount due from/to an intermediate parent company	**117**	139	**–**	–
Amounts due from/to fellow subsidiaries:				
Shenzhen Neptunus Pharmaceutical Co., Ltd	**47,631**	13,016	**2,660**	3,293
Shandong Neptunus Yinhe Pharmaceutical Company Limited	**1,001**	790	**1,363**	1,823
Shenzhen Neptunus Yinhe Pharmaceutical Investment Company Limited	**–**	–	**49,000**	25,000
Anhui Neptunus Pharmaceutical Group Company Limited	**–**	57	**–**	–
Henan Neptunus Pharmaceutical Group Company Limited	**455**	–	**–**	–
Neptunus (Shaoguan) Pharmaceutical Company Limited (Non-related company)	**–**	–	**–**	6
Shenzhen Quanyaowang Pharmaceutical Company Limited	**856**	856	**–**	–
Shenzhen Neptunus Property Management Company Limited	**67**	71	**–**	–
Henan Neptunus Yinhe Pharmaceutical Company Limited	**–**	–	**24**	24
Qingdao Huaren Pharmaceutical Distribution Company Limited	**37**	2	**–**	3
Henan Neptunes Pharmaceutical Group Company Limited	**–**	405	**–**	–

17. MATERIAL RELATED PARTY TRANSACTIONS (CONTINUED)

(b) Outstanding balances with related parties (Continued)

Name of related parties	Amounts due from related parties		Amounts due to related parties	
	At 30 June 2026 RMB'000 (Unaudited)	At 31 December 2025 RMB'000 (Audited)	**At 30 June 2026 RMB'000 (Unaudited)**	At 31 December 2025 RMB'000 (Audited)
Heilongjiang Province Neptunus Pharmaceutical Company Limited	**37**	56	**–**	–
Henan Enji Pharmaceutical Company Limited	**11**	12	**–**	–
Guangdong Neptunus Medical Group Company Limited	**2,036**	1,850	**–**	–
Henan Guanbao Yuntong Pharmaceutical Company Limited	**37**	37	**–**	–
Henan Zuojinming Pharmaceutical Company Limited	**24**	50	**–**	–
Kashi Neptunus Yinhe Pharmaceutical Company Limited	**–**	–	**20**	–
Shenzhen Neptunus Medical Health Company Limited	**31**	–	**–**	–
Hubei Neptunus Pharmaceutical Group Company Limited	**–**	6	**–**	8
Fuzhou Nepstar Health Drugstore Chain Company Limited	**–**	2	**–**	–
Neptunus (Zhanjiang) Pharmaceutical Company Limited	**–**	–	**–**	2
	52,223	17,210	**53,067**	30,159

17. MATERIAL RELATED PARTY TRANSACTIONS (CONTINUED)

(b) Outstanding balances with related parties (Continued)

Name of related parties	Amounts due from related parties		Amounts due to related parties	
	At 30 June 2026 RMB'000 (Unaudited)	At 31 December 2025 RMB'000 (Audited)	**At 30 June 2026 RMB'000 (Unaudited)**	At 31 December 2025 RMB'000 (Audited)
Amounts due from/to related companies:				
Shenzhen Neptunus Yidiangao Pharmaceutical Company Limited	**17,045**	19,990	**–**	–
Jiangsu Nepstar Pharmaceutical Company Limited	**12,009**	9,251	**–**	–
Jilin Neptunus Jiankang Bio-technology Company Limited	**3,000**	4,000	**–**	–
Nanning Neptunus Jiankang Bio-technology Company Limited	**3,000**	3,000	**55**	4
Liaoning Province Nepstar Pharmaceutical Trading Company Limited	**7,098**	4,975	**–**	–
Shenzhen Nepstar Health Drugstore Chain Company Limited	**1,167**	–	**–**	–
Fuzhou Nepstar Health Drugstore Chain Company Limited	**63**	–	**–**	–
	43,382	41,216	**55**	4
	95,730	58,565	**53,241**	30,963

* The English translation of the Chinese name in these consolidated financial statements, where indicated, is included for information purpose only.

17. MATERIAL RELATED PARTY TRANSACTIONS (Continued)

(b) Outstanding balances with related parties (Continued)

The balances with related parties are unsecured, interest-free and repayable on demand.

The Group's amounts due from/to related parties which are of trade nature and non-trade nature, consisted of the following:

	Amounts due from related parties		Amounts due to related parties	
	At 30 June 2026 RMB'000 (Unaudited)	At 31 December 2025 RMB'000 (Audited)	**At 30 June 2026 RMB'000 (Unaudited)**	At 31 December 2025 RMB'000 (Audited)
Trade nature				
Amounts due from/to fellow subsidiaries	**52,156**	16,970	**4,067**	4,159
Amounts due from/to related companies	**43,382**	41,216	**55**	4
Amount due from an immediate parent company	**8**	–	**–**	–
	95,546	58,186	**4,122**	4,163
Non-trade nature				
Amount due to an immediate parent company	**–**	–	**119**	800
Amount due from/to an intermediate parent company	**117**	139	**–**	–
Amounts due from/to fellow subsidiaries	**67**	240	**49,000**	26,000
	184	379	**49,119**	26,800
	95,730	58,565	**53,241**	30,963

17. MATERIAL RELATED PARTY TRANSACTIONS (CONTINUED)

(b) Outstanding balances with related parties (Continued)

The ageing analysis of amounts due from related parties arising from the ordinary course of business which are of trade nature, based on invoice date, is as follows:

	At 30 June 2026 RMB'000 (Unaudited)	At 31 December 2025 RMB'000 (Audited)
Within 3 months	**38,150**	35,064
More than 3 months but less than 12 months	**38,473**	22,266
Over 12 months	**18,923**	856
	95,546	58,186

The ageing analysis of amounts due to related parties arising from the ordinary course of business which are of trade nature, based on invoice date, is as follows:

	At 30 June 2026 RMB'000 (Unaudited)	At 31 December 2025 RMB'000 (Audited)
Within 3 months	**4,098**	4,163
More than 3 months but less than 12 months	**24**	–
	4,122	4,163

(c) Key management personnel remuneration

	For the six months ended 30 June	
	2026 RMB'000 (Unaudited)	2025 RMB'000 (Unaudited)
Short-term employee benefits	**2,573**	2,634
Post-employment benefits	**135**	144
	2,708	2,778

MANAGEMENT DISCUSSION AND ANALYSIS

BUSINESS REVIEW

During the Reporting Period, the Group was principally engaged in the research and development, manufacturing and selling of medicines and medical devices, and the purchase and sales of medicines, healthcare food products and medical devices in the PRC. The medicines being sold by the Group mainly cover several therapeutic areas which are oncology, cardiovascular system, respiratory system, digestive system and mental diseases.

Research and Development, Manufacturing and Selling of Medicines and Medical Devices

The Group has two pharmaceutical production bases, which are respectively located in Jin'an District, Fuzhou, Fujian Province, the PRC ("Fuzhou Production Base") and Miyun Economic Development Zone, Beijing Municipality, the PRC ("Beijing Production Base"). The Fuzhou Production Base possesses 368 Guo Yao Zhun Zi approval documents for Chinese medicines (including more than a dozen of dosage forms such as tablets, capsules, granules, oral solutions and tinctures) and chemical medicines (which include various dosage forms namely tablets, capsules, granules, small volume injections and large volume injections) in total, of which 236 varieties are included in the "Catalogue of Drugs for Basic National Medical Insurance" (國家基本醫療保險藥品目錄), and 133 products are included in the "National Essential Drug List" (國家基本藥品目錄). Meanwhile, the Fuzhou Production Base is the only narcotic combination drugs production base in Fujian Province designated by the State. The Beijing Production Base mainly produces chemical medicines (tablets, hard capsules, powders and granules) and holds 137 Guo Yao Zhun Zi approval documents, of which 90 products are included in the "Catalogue of Drugs for Basic National Medical Insurance" (國家基本醫療保險藥品目錄) (64 Basic Medical Insurance Category A drugs and 26 Basic Medical Insurance Category B drugs), 54 products are included in the "National Essential Drug List" (國家基本藥品目錄), and 31 OTC products (23 in Category A and 8 in Category B).

The Group's research and development work mainly fulfills the internal development demands of the Group through conducting independent research and development and cooperation with external research and development institutions. Three pharmaceutical manufacturing subsidiaries of the Company are recognized as high-tech enterprises and all of them are entitled to enjoy preferential corporate income tax treatment for high-tech enterprises. Over the years, the Group has consistently promoted its research and development innovation strategy and continued to invest in the consistency evaluation of generic medicine and the research and development of new medicines. Currently, the Group owns a total of 76 patents, including 29 invention patents, 4 appearance patents and 43 utility model patents. In respect of consistency evaluation, five of the Group's products have passed the consistency evaluation, including Sodium Bicarbonate Tablets (碳酸氫鈉片), Norfloxacin Capsules (諾氟沙星膠囊), Metformin Hydrochloride Tablets (鹽酸二甲雙胍片), Propranolol Hydrochloride Tablets (鹽酸普萘洛爾片) and Atropine Sulfate Injection (硫酸阿托品注射液). In addition, Vitamin B6 Tablets (維生素B6片) has obtained the supplementary application approval. The consistency evaluation of folic acid tablets (葉酸片) has completed the review process and a request for supplementary information has been received. The consistency evaluation of bumetanide injection (布美他尼注射液) has been accepted for review and is currently under evaluation. In the aspect of research and development of new medicines, Doxofylline Injection (多索茶鹼注射液), Concentrated Sodium Potassium Magnesium Calcium Injection (鈉鉀鎂鈣注射用濃溶液) and Sodium Bicarbonate Ringer's Injection (碳酸氫鈉林格注射液), which are the holder varieties of the Company's pharmaceutical subsidiary, and generic Sildenafil Citrate Orodispersible Tablets (枸櫞酸西地那非口崩片), a self-developed variety, have obtained approval. The Group also possesses various new drugs and exclusive products with self-owned intellectual property rights, including Tegafur, Gimeracil and Oteracil Potassium Tablets (the "TGOP Tablets" or 替吉奧片, a drug for anti-gastric cancer), Xiaozheng Yigan Tablets (消症益肝片, an anti-liver-cancer drug), Proteoglycan Tablets (多糖蛋白片, for enhancing the immune system), Biyuan Capsules (鼻淵膠囊, an anti-rhinitis medicine), Amaranth Berberine Capsules (莧菜黃連素膠囊, a drug for acute diarrhea), Disodium Glycyrrhizinate (甘草酸二鈉, a drug for anti-inflammatory and liver protection), Spironolactone Tablets (螺內酯片, a drug for auxiliary diuresis), Ligustrazine Phosphate Tablets (磷酸川芎嗪片, a drug for ischemic cerebrovascular disease), Pre-filled Catheter Flusher (預充式導管沖洗器, a Class III medical device) and HTK Myocardial Protection Cardioplegic Solution (HTK 心肌保護停跳液, a Class III medical device).

During the Reporting Period, two pharmaceutical subsidiaries of the Group located in Fujian followed the current acting strategy to unify sales policy, complement strengths, allocate resources, cross-hold and integrate development to fully expand the market of key products. At the provincial level, the Group utilized the home advantages and resources to essentially achieve commercial full coverage; while outside the province, the Group utilized the national market resources and customer resources of Neptunus Headquarters, and gave full play to the advantages of the linkage between the industrial system and trade system of Neptunus Headquarters to continue to expand the market. Also, the Group specifically participated in volume-based procurement initiatives with provincial-level alliances, deepened the development of primary, county-level and community healthcare markets. Meanwhile, according to the characteristics of the products, the distribution channels are divided into three major channels, namely, omnichannel sales, controlled sales and e-commerce sales for the purpose of sales layouts, so as to continuously open up the sales channels and adopt a complementary approach between the medical institutions and the distribution market, so as to consolidate and develop the original advantageous products' share in the medical institutions. Among the subsidiaries, Fuzhou Neptunus Fuyao Pharmaceutical Company Limited adhered to its core competitive products, and steadily improved its operating results by expanding the market through multiple channels and cultivating new growth points in product sales under the promise of implementing key works in the areas of quality, safety and standardization; while Fuzhou Neptunus Jinxiang Chinese Pharmaceutical Company Limited ("Neptunus Jinxiang") continued to focus on the production of fine Chinese medicines, while implementing the philosophy of "safeguarding the integrity of inheritance, securing and innovative, and producing fine Chinese medicines", actively upgrading product positioning, striving to expand its market share in fine Chinese medicines, cultivating key product varieties, consolidating existing market presence and share, and driving incremental growth. Meanwhile, Neptunus Jinxiang fully leveraged the strengths of resources within its systems and sales teams, and aligned its policies to achieve synergistic resources allocation and integrated development. Affected by a variety of factors, the results of the two pharmaceutical subsidiaries declined to a relatively large extent during the Reporting Period. Specifically, it was mainly due to the implementation of new policies, adjusted models of product sales and the decreased market demands. The efforts made by these pharmaceutical subsidiaries in terms of production quality, channel expansion, optimization of procurement structure, and inventory management, etc. will continuously strive to stem the downtrend as soon as possible.

Given the continuous advancement of national centralized procurement, price fluctuations of raw materials, and increasingly stringent regulatory environment on quality, Beijing Neptunus Zhongxin Pharmaceutical Co., Ltd. ("Neptunus Zhongxin"), a pharmaceutical manufacturing subsidiary of the Group located in Beijing, proactively followed the industry policies and the market changes by means of expanding its production capacity, increasing production, strictly enforcing quality control, adjusting the portfolio structure, transforming the marketing model and the team, etc., while closely focusing on the strategic layout of "shifting products from low gross profit to high gross profit, and expansion of consignment and contract processing business model", strengthening budget and compliance management, reducing costs and increasing efficiency, and further refining risk control. Meanwhile, Neptunus Zhongxin also proactively promoted the transformation of its product mix for sales, which was changing from the distribution of general pharmaceutical products to a new model of "healthcare services integrated with drug distribution", to create a more competitive business landscape. During the Reporting Period, the revenue of Neptunus Zhongxin increased as compared with the corresponding period last year, with its loss being improved as well. Neptunus Zhongxin will continue to carry out operational adjustment programs such as transformation of marketing model and deepening development of target markets; optimize pricing, channel and competition strategies of products; intensify its efforts in budgets control, paybacks focus, receivables reduction, winning bids and risk prevention; production capacity expansion and ongoing transformation; and strive to turn the business around to profitability as soon as possible.

Purchase and Sales of Medicines, Healthcare Food Products and Medical Devices

Currently, the main products distributed and sold by the Group are medicines and healthcare food products manufactured by the Group and its parent company group, which include the well-known product series of the Neptunus Ginkgo Leaves Tablets (海王銀杏葉片) and Neptunus Jinzun (海王金樽). Meanwhile, the Group initiated the distribution of medical devices. Such products are mainly distributed to the end medical institutions through professional sales promotion companies and to the end users through large and medium-sized chain pharmacies. Over the past two years, adjusted medical insurance policies, tightened medical insurance coverage, stricter regulation on retail end and other external factors have continued to adversely affect the purchase and sales operations on medicine and healthcare food products of the Group. In order to stabilize its business and safeguard its long-term development, the Group's medicines and healthcare food products division will continue to focus on integrated planning, promptly optimize its product portfolio, channel distribution, and customer matching strategies in alignment with policy directives, while focusing on the sales of key products and vigorously developing the healthcare food products market. Meanwhile, by putting more effort into the promotion of its products and brand through self-media and further boosting the sales and results of its key products, the Group strove to cultivate new flagship products.

Since 2022, Fuzhou Fuyao Medical Company Limited ("Fuyao Medical"), the purchasing and selling subsidiary of the Group located in Fuzhou, has been achieving significant results in the expansion of the purchasing and selling business of medical devices and the regional distribution of medicines, and has established a stable and efficient sales network for the distribution of medicines and medical devices to public medical institutions in Fuzhou. Fuyao Medical will continue to strengthen its efforts in cultivating end medical institutions and establish a new team responsible for sales growth to ensure its solid performance over the long term.

During the Reporting Period, the results of the Group's medicines and healthcare food purchases and sales division declined to a relatively large extent as compared with the corresponding period of last year.

FINANCIAL REVIEW

The Group's revenue during the Reporting Period was approximately RMB436,165,000, representing a decrease of approximately 12.05% from approximately RMB495,920,000 for the corresponding period of last year. In relation to the Group's revenue, approximately RMB216,828,000, which amounted to approximately 49.71% of the Group's total revenue, was derived from the manufacturing and selling of medicines and medical devices segment, while approximately RMB219,337,000, which amounted to approximately 50.29% of the Group's total revenue, was derived from the sales and distribution of medicines, healthcare products and medical devices segment.

During the Reporting Period, the Group's gross profit margin was approximately 31%, representing a decrease of approximately 1 percentage point from approximately 32% for the corresponding period of last year. The decrease in gross profit margin compared with the previous year was mainly due to reduction in unit prices and adjustments to the sales model following the implementation of centralized procurement of medicines and regulatory policies governing medicine pricing.

The Group's gross profit during the Reporting Period was approximately RMB133,349,000, representing a decrease of approximately 15.79% from approximately RMB158,354,000 for the corresponding period of last year. The decrease in the gross profit was mainly attributable to the decrease in the Group's revenue and gross profit margin.

During the Reporting Period, the Group's selling and distribution expenses were approximately RMB58,645,000, representing a decrease of approximately 20.88% from approximately RMB74,120,000 for the corresponding period of last year. The decrease in selling and distribution expenses was mainly due to the decrease in revenue and a change in the sales model of certain products, which led to the corresponding decrease in selling and distribution expenses.

The Group's administrative expenses for the Reporting Period were approximately RMB45,440,000, which remained largely unchanged as compared with approximately RMB45,050,000 for the corresponding period of last year.

During the Reporting Period, the Group's other operating expenses and other receivables and other impairment/reversal on receivables, net amounted to approximately RMB19,158,000, representing a decrease of approximately 18.07% from approximately RMB23,383,000 for the corresponding period of last year. The decrease was mainly due to the decrease in research and development expenses and a reduction in provisions for impairment of inventories.

The Group's finance costs for the Reporting Period amounted to approximately RMB1,754,000, representing a decrease of approximately 21.91% as compared with RMB2,246,000 for the corresponding period of last year. The decrease in finance costs was mainly due to the decrease in interest expenses on the bank loans of Neptunus Zhongxin.

For the reasons above, the Group's profit after tax decreased from approximately RMB22,041,000 for the corresponding period of last year to approximately RMB8,910,000 for the Reporting Period, representing a decrease of approximately 59.57%. The profit attributable to the owners of the Company decreased from approximately RMB19,065,000 for the corresponding period of last year to approximately RMB7,042,000 for the Reporting Period, representing a decrease of approximately 63.06%.

LIQUIDITY AND FINANCIAL RESOURCES

The Group usually finances its operating and investing activities with its internal financial resources and bank loans. The Group's transactions and borrowings are mainly denominated in RMB and the Group reviews its demand for working capital and financing on a regular basis.

BANKING FACILITIES

As at 30 June 2026, the Group had short-term bank borrowings of RMB88,879,000, and the interest rates applied were primarily subject to floating fixed interest rates.

PLEDGE OF ASSETS

As at 30 June 2026, the available banking facilities of RMB61,000,000 of the Group were secured by pledge of its buildings and the pledged buildings were stated at an aggregate carrying amount of approximately RMB20,385,000.

As at 30 June 2026, the Group's furniture, fixtures and equipment with a carrying amount of RMB2,201,000 were pledged to secure the Group's other borrowings.

FOREIGN CURRENCY RISK

During the Reporting Period, the Group's operating revenue, major selling costs and capital expenditure were denominated in RMB. As at 30 June 2026, the Group's cash and cash equivalents were mainly denominated in RMB. As such, the foreign currency risk facing the Group is limited. Currently, the Group has not adopted any financial instrument for hedging purposes.

GEARING RATIO

As at 30 June 2026, the gearing ratio of the Group, calculated by dividing the total liabilities by total equity and multiplied by 100%, was approximately 50.70% (31 December 2025: approximately 50.08%).

SIGNIFICANT INVESTMENT HELD

Save as disclosed in this announcement, there was no other significant investment held by the Company during the Reporting Period.

CAPITAL STRUCTURE

During the Reporting Period, there has been no change in the capital structure of the Company. The capital of the Company comprises its shares and other reserves.

INTERIM DIVIDEND

The Board did not recommend the payment of any interim dividend for the Reporting Period (six months ended 30 June 2025: Nil).

MATERIAL ACQUISITIONS AND DISPOSALS OF SUBSIDIARIES, ASSOCIATES AND JOINT VENTURES

The Group had not made any material acquisitions and disposals of subsidiaries, associates, and joint ventures during the Reporting Period.

CONTINGENT LIABILITY

As at 30 June 2026, the Group had no significant contingent liability.

FUTURE PLANS FOR MATERIAL INVESTMENTS AND CAPITAL ASSETS

As at 30 June 2026, the Group did not have concrete plans for material investments and capital assets.

NO MATERIAL CHANGE

Save as disclosed in this announcement, during the six months ended 30 June 2026, there has been no material change in the Group's financial position or business since the publication of the latest annual report of the Company for the year ended 31 December 2025.

EMPLOYEES AND REMUNERATION POLICY

As at 30 June 2026, the Group employed a total of 1,321 employees.

During the Reporting Period, the staff costs (including directors' remuneration) amounted to approximately RMB78,481,000. Employees are remunerated according to their performance and work experience. The Group raised the salaries and improved fringe benefits for its employees to maintain competitiveness and broaden appeal of the Group. The employees' incentives were reviewed and determined annually pursuant to the remuneration, bonus policies and/or share options of the Group based on the performance of the employees. The Group also provided various other benefits to its employees.

The Group monitored closely the remuneration and fringe benefits of the employees and rewarded employees in accordance with the Group's business performance. In addition, training and development opportunities for the employees were also provided by the Group.

CAPITAL COMMITMENTS

As at 30 June 2026, the Group had contracted commitments for future capital expenditure of approximately RMB4,184,000. The Board believes that such capital expenditure can be financed by the Group's bank deposits and bank borrowings.

INTERESTS AND SHORT POSITIONS OF DIRECTORS AND CHIEF EXECUTIVE IN THE LISTED SECURITIES

As far as the Directors are aware, as at 30 June 2026, the interests and short positions of the Directors and chief executive of the Company in the shares, underlying shares and debentures of the Company and its associated corporations (within the meaning of Part XV of the Securities and Futures Ordinance (the "SFO")) which were required to be notified to the Company and the Stock Exchange pursuant to Part XV of the SFO (including interests or short positions which they were taken or deemed to have under such provisions of the SFO), or were required, pursuant to section 352 of the SFO, to be and were recorded in the register to be kept by the Company, or were required, pursuant to Rule 5.46 to Rule 5.67 of the GEM Listing Rules to be notified to the Company and the Stock Exchange were as follows:

Long positions in shares of associated corporations of the Company:

Director	**Capacity**	**Type of interests**	**Name of associated corporation**	**Number of ordinary shares held in associated corporation**	**Approximate percentage of the associated corporation's issued share capital *(Note (b))***
Mr. Zhang Feng *(Note (a))*	Beneficial owner	Personal	Neptunus Bio-engineering	1,631,793	0.06%

Notes:

(a) Mr. Zhang Feng, chairman of the Board, and chairman, non-independent director of the 10th session of the board of directors, the president, the chairman of the strategy development and research committee, the chairman of the budget committee, a member of the remuneration and evaluation committee and a member of the nomination committee of Neptunus Bio-engineering, was beneficially interested in approximately 0.06% of the entire issued share capital of Neptunus Bio-engineering, the Company's controlling shareholder, which in turn held directly and indirectly the beneficial interest in approximately 73.51% of the entire issued share capital of the Company, of which 70.38% was directly held and 3.13% was indirectly held through Shenzhen Neptunus Oriental Investment Company Limited ("Neptunus Oriental").

(b) The calculation of approximate percentage of the associated corporation's issued share capital was based on the total number of 2,631,123,257 shares in issue of that associated corporation as at 30 June 2026.

Save as disclosed above, as at 30 June 2026, none of the Directors or chief executive of the Company nor their respective associates held any interests or short positions in the shares, underlying shares or debentures of the Company or any of its associated corporations (within the meaning of Part XV of the SFO), which were required to be notified to the Company and the Stock Exchange pursuant to Part XV of SFO, or were required, pursuant to section 352 of the SFO to be and were recorded in the register to be kept by the Company, or were required, pursuant to Rule 5.46 to Rule 5.67 of the GEM Listing Rules, to be notified to the Company and the Stock Exchange.

SHARE SCHEME, CONVERTIBLE SECURITIES AND WARRANTS

Up to 30 June 2026, the Company and its subsidiaries have neither adopted any share scheme nor granted any option, convertible securities, warrants or other similar rights.

DIRECTORS' SHARE OPTIONS, WARRANTS OR CONVERTIBLE BONDS

At any time during the Reporting Period, none of the Directors or their respective spouse or minor children were granted any share options, warrants or convertible bonds of the Company, its subsidiaries or associated corporation.

SUBSTANTIAL SHAREHOLDERS' INTERESTS IN SHARES AND UNDERLYING SHARES

So far as the Directors are aware, as at 30 June 2026, the interests and/or short positions held by shareholders (not being a Director or a chief executive of the Company) in shares or underlying shares of the Company which were recorded in the register required to be kept by the Company pursuant to Section 336 of the SFO or otherwise notified to the Company were as follows:

Long positions in the shares of the Company:

Substantial Shareholder	**Capacity**	**Number of domestic shares held**	**Approximate percentage of all the domestic shares *(Note (e))***	**Approximate percentage of the Company's issued share capital *(Note (f))***
Neptunus Bio-engineering *(Note (a))*	Beneficial owner	1,181,000,000	94.33%	70.38%
	Interest in controlled corporation	52,464,500	4.19%	3.13%
Shenzhen Neptunus Group Company Limited ("Neptunus Group") *(Note (b))*	Interest in controlled corporation	1,233,464,500	98.52%	73.51%
Neptunus Holding *(Note (c))*	Interest in controlled corporation	1,233,464,500	98.52%	73.51%
Mr. Zhang Si Min *(Note (d))*	Interest in controlled corporation	1,233,464,500	98.52%	73.51%

Notes:

(a) Neptunus Bio-engineering was deemed to be interested in the 52,464,500 domestic shares of the Company held by Neptunus Oriental as the entire issued share capital of Neptunus Oriental was beneficially owned by Neptunus Bio-engineering. Neptunus Bio-engineering was also directly interested in 1,181,000,000 domestic shares of the Company. Therefore, Neptunus Bio-engineering was directly and indirectly interested in 1,233,464,500 domestic shares of the Company.

(b) Neptunus Group was deemed to be interested in the 1,233,464,500 domestic shares of the Company, which relate to the same parcel of shares referred to in note (a) above, held by Neptunus Bio-engineering as Neptunus Group was beneficially interested in approximately 46.23% of the entire issued share capital of Neptunus Bio-engineering.

(c) Neptunus Holding was deemed to be interested in 1,233,464,500 domestic shares of the Company, which relate to the same parcel of shares referred to in note (a) above, held by Neptunus Bio-engineering as Neptunus Holding was beneficially interested in approximately 59.68% of the entire issued share capital of Neptunus Group, which in turn was beneficially interested in approximately 46.23% of the entire issued share capital of Neptunus Bio-engineering.

(d) Mr. Zhang Si Min ("Mr. Zhang") was deemed to be interested in 1,233,464,500 domestic shares of the Company, which relate to the same parcel of shares referred to in note (a) above, held by Neptunus Bio-engineering as Mr. Zhang was beneficially interested in 70% of the entire issued share capital of Neptunus Holding and the entire issued share capital of Shenzhen Haihe Investment and Development Company Limited ("Haihe"), which in turn was beneficially interested in approximately 59.68% and 20% of the entire issued share capital of Neptunus Group respectively, and Neptunus Group was beneficially interested in approximately 46.23% of the entire issued share capital of Neptunus Bio-engineering.

(e) The calculation of approximate percentage of all the domestic shares was based on the total number of 1,252,000,000 domestic shares in issue as at 30 June 2026.

(f) The calculation of approximate percentage of the Company's issued share capital was based on the total number of 1,678,000,000 shares in issue as at 30 June 2026.

Save as disclosed above, the Directors are not aware of any other persons (except the Directors or chief executive of the Company) who held any interests or short positions in the shares or underlying shares of the Company as recorded in the register required to be kept by the Company pursuant to section 336 of the SFO as at 30 June 2026.

PURCHASE, SALE OR REDEMPTION OF THE LISTED SECURITIES OF THE COMPANY

The Company and its subsidiaries did not purchase, redeem or sell any of the Company's listed securities, nor were there any sales of treasury shares of the Company during the Reporting Period. The Company and its subsidiaries also did not redeem, purchase or cancel any of their redeemable securities. There were no treasury shares held by the Company during the Reporting Period.

COMPETING INTERESTS

On 21 August 2005, Neptunus Bio-engineering, the controlling shareholder of the Company, entered into an agreement with the Company containing undertakings relating to non-competition and preferential rights of investments (the "Non-Competition Undertakings"), pursuant to which Neptunus Bio-engineering had undertaken to the Company and its associates that, inter alia, as long as the securities of the Company are listed on GEM (previously known as Growth Enterprise Market):

1. it will not, and will procure its associates not to, whether within or outside the PRC, directly or indirectly (other than those indirectly held as a result of the equity interest in any listed company or its subsidiaries), participate in or operate any business in whatever form, or produce any products, (the usage of which is the same as or similar to that of the products of the Company) which may constitute direct or indirect competition to the business operated by the Company from time to time; and

2. it will not, and will procure its associates not to hold any interest, whether within or outside the PRC, in any company or organization (directly or indirectly, other than indirectly held as a result of its equity interest in any listed company or its subsidiaries) when the business of such company or entity will (or may) compete directly or indirectly with the business of the Company.

Pursuant to the Non-Competition Undertakings, at a time when the Non-Competition Undertakings are subsisting, whenever Neptunus Bio-engineering or any its associates enter into any negotiations, within or outside the PRC, in relation to any new investment project which may compete with the existing and future business of the Company, the Company shall have a preferential right of investment in such new investment projects.

Neptunus Bio-engineering has confirmed with the Company that it has complied with the Non-Competition Undertakings during the Reporting Period.

CODE OF CONDUCT REGARDING SECURITIES TRANSACTIONS BY DIRECTORS

During the Reporting Period, the Company has adopted a code of conduct regarding securities transactions by Directors on terms no less exacting than the "required standard of dealings" as set out in Rules 5.48 to 5.67 of the GEM Listing Rules. Having made specific enquiry of all the Directors, all the Directors confirmed that they have complied with the "Required Standard of Dealings" and the Company's code of conduct regarding Director's securities transactions.

AUDIT COMMITTEE

The Company established an audit committee (the "Audit Committee") on 21 August 2005. The primary duties of the Audit Committee are to review the Company's annual report, financial statements and half-yearly reports, and to provide suggestions and opinions thereon to the Board. In addition, the Audit Committee members will also meet with the management to review the accounting principles and practices adopted by the Company and to discuss matters relating to the auditing, internal control system and financial reporting process of the Company. The Audit Committee comprises one non-executive Director, namely Mr. Jin Rui and two independent non-executive Directors, namely Mr. Yick Wing Fat, Simon and Mr. Poon Ka Yeung. Mr. Yick Wing Fat, Simon is the chairman of the Audit Committee.

The Audit Committee has reviewed the unaudited condensed consolidated results of the Group for the Reporting Period.

COMPLIANCE WITH THE CORPORATE GOVERNANCE CODE

The Company puts strong emphasis on the superiority, steadiness and rationality of corporate governance. The Company has applied the principles of the "Corporate Governance Code" as set out in Appendix C1 to the GEM Listing Rules ("CG Code") to its corporate governance structure and practices. The Board is of the view that the Company has complied with the requirements set out in the CG Code throughout the Reporting Period, except for the deviation as set out below.

According to code provision B.2.4 of the CG Code, where all the independent non-executive directors of an issuer have served more than nine years on the board, the issuer should, among other actions, appoint a new independent non-executive director to the board at the forthcoming annual general meeting.

Ms. Zhu Jia Min has been appointed as a new independent non-executive Director at the annual general meeting held on 25 June 2026. The Company has complied with the requirement set out in code provision B.2.4 of the CG Code.

Save as disclosed, as the Directors are aware, throughout the Reporting Period, the Company has complied with the requirements under the CG Code. The Board will continue to enhance the standard of corporate governance of the Company to ensure that the Company will operate its business in an honourable and responsible manner.

CHANGES IN DIRECTOR'S INFORMATION

Since the publication date of the 2025 Annual Report of the Company and up to the date of this announcement, there was no change in the information of the Directors and chief executives which is required to be disclosed pursuant to Rule 17.50A(1) of the GEM Listing Rules.

EVENTS AFTER THE REPORTING PERIOD

Save as disclosed above, there are no other important events affecting the Group which have occurred after the end of the Reporting Period and up to the date of this announcement.

On behalf of the Board
Shenzhen Neptunus Interlong Bio-technique Company Limited*
Zhang Feng
Chairman

Shenzhen, the PRC, 25 August 2026

As at the date of this announcement, the executive Directors are Mr. Zhang Feng, Mr. Huang Jian Bo and Mr. Zhang Xiao Guang; the non-executive Directors are Mr. Zhang Yi Fei, Mr. Jin Rui and Mr. Zhang Xiao Peng; and the independent non-executive Directors are Mr. Yick Wing Fat, Simon, Mr. Poon Ka Yeung and Ms. Zhu Jia Min.

* *For identification purpose only*